



**1199 SEIU Benefit Funds
Outpatient Medical Oncology Program**

Effective: 07/01/22

Description	Alt Descriptions	HCPDS Code	Program	Drug Class	Administration Technique	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
5-Fluorouracil - Topical	5FU Cream, Efidex, Carac, Fluoroplex	J3490	Medical Oncology - CHEMO	Primary	TOPICAL		Y	
5-Fluorouracil- Injection	5FU, Adrucil	J9190	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Abemaciclib - oral	Verzenio	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Abiraterone Acetate - oral	Yonsa (not interchangeable with Zytiga)	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Abiraterone Acetate - oral	Zytiga (not interchangeable with Yonsa)	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Acalabrutinib - oral	Calquence	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Acitretin - oral	Soriatane	J8499	Medical Oncology - CHEMO	Primary	ORAL		Y	
Ado-Trastuzumab Emtansine	Kadcyla	J9354	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Afatinib - oral	Gilotrif	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Aldesleukin	Proleukin, Interleukin-2	J9015	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Alectinib - oral	Alecensa	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
All-trans Retinoic Acid - oral	Vesanoid, ATRA, Tretinoin	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Alpelisib - oral	Piqray	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Amivantamab-vmjw	Rybrevant	J9061	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Apalutamide - oral	Erleada	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Aprepitant	Cinvanti	J0185	Medical Oncology - SPORT	Supportive - Antiemetic	INJECTABLE		Y	
Aprepitant - oral	Emend	J8501	Medical Oncology - SPORT	Supportive - Antiemetic	ORAL		Y	
Arsenic Trioxide	Trisenox	J9017	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Asciminib - oral	Scemblix	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Asparaginase	Erwinaze	J9019	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Asparaginase erwinia chrysanthemii (recombinant)-rywn	Rylaze	J9021	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Atezolizumab	Tecentriq	J9022	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Avapritinib - oral	Ayvakit	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Avelumab	Bavencio	J9023	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Axitinib - oral	Inlyta	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Azacitidine	Vidaza	J9025	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Azacitidine - oral	Onureg	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	Medicare Part B

Outpatient Medical Oncology Program

Description	Alt Descriptions	HCPCS Code	Program	Drug Class	Administration Technique	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
BCG	TheraCys, Tice	J9030	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Belantamab Mafodotin-blmf	Blenrep	J9037	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Belinostat	Beleodaq	J9032	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Belzutifan - oral	Welireg	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Bendamustine HCL	Belrapzo	J9036	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Bendamustine HCL	Bendeka	J9034	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Bendamustine hcl	Treanda	J9033	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Bevacizumab	Avastin	J9035	Medical Oncology - CHEMO	Primary	INJECTABLE	◆	Y	
Bevacizumab (Radiation Necrosis)	Avastin	J9035	Medical Oncology - SPORT	Supportive	INJECTABLE	◆	Y	New supportive pathway for the use of Avastin to treat Radiation Induced Necrosis of the CNS
Bevacizumab-awwb	Mvasi	Q5107	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	◆	Y	
Bevacizumab-awwb (Radiation Necrosis)	Mvasi	Q5107	Medical Oncology - SPORT	Supportive	INJECTABLE	◆	Y	New supportive pathway for the use of Mvasi to treat Radiation Induced Necrosis of the CNS
Bevacizumab-bvzr	Zirabev	Q5118	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	◆	Y	
Bevacizumab-bvzr (Radiation Necrosis)	Zirabev	Q5118	Medical Oncology - SPORT	Supportive	INJECTABLE	◆	Y	New supportive pathway for the use of Zirabev to treat Radiation Induced Necrosis of the CNS
Bevacizumab-maly	Allysys	C9399	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	◆	Y	NOC Code: C9399 for new primary biosimilar chemotherapy drug effective: 05/04/22
Bevacizumab-maly	Allysys	J9999	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	◆	Y	NOC Code: J9999 for new primary biosimilar chemotherapy drug effective: 05/04/22
Bevacizumab-maly (Radiation Necrosis)	Allysys	J9999	Medical Oncology - SPORT	Supportive	INJECTABLE	◆	Y	NOC Code J9999 for new supportive drug effective: 06/04/22
Bexarotene - oral	Targretin	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Bexarotene - topical	Targretin gel	J3490	Medical Oncology - CHEMO	Primary	TOPICAL		Y	
Binimetinib - oral	Mektovi	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Bleomycin	Blenoxane	J9040	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Blinatumomab	Blincyto	J9039	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Bortezomib	Bortezomib (not otherwise specified)	J9044	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Bortezomib	Velcade	J9041	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Bosutinib - oral	Bosulif	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Brentuximab Vedotin	Adcetris	J9042	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Brigatinib - oral	Alunbrig	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Burosumab-twza	Crysvisa	J0584	Medical Oncology - SPORT	Supportive	INJECTABLE	◆	Y	
Cabazitaxel	Jevtana	J9043	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	

Effective: 07/01/22

Outpatient Medical Oncology Program

Description	Alt Descriptions	HCPCS Code	Program	Drug Class	Administration Technique	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Cabozantinib - oral	Cabometyx	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Cabozantinib - oral	Cometriq	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Calaspargase pegol-mknl	Asparlas	J9118	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Capecitabine - oral	Xeloda (150 mg)	J8520	Medical Oncology - CHEMO	Primary	ORAL		Y	Medicare Part B
Capecitabine - oral	Xeloda (500 mg)	J8521	Medical Oncology - CHEMO	Primary	ORAL		Y	Medicare Part B
Capmatinib - oral	Tabrecta	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Carboplatin	Paraplatin	J9045	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Carfilzomib	Kyprolis	J9047	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Carmustine	BICNU, BCNU	J9050	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Cemiplimab-rwlc	Libtayo	J9119	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Ceritinib - oral	Zykadia	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Cetuximab	Erbixux	J9055	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Chlorambucil - oral	Leukeran	J8999	Medical Oncology - CHEMO	Primary	ORAL	◆	Y	Medicare Part B
Chlorambucil - oral	Leukeran	S0172	Medical Oncology - CHEMO	Primary	ORAL	◆	Y	Medicare Part B
Cisplatin	Platinol	J9060	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Cladribine	Leustatin	J9065	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Clofarabine	Clolar	J9027	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Cobimetinib - oral	Cotellic	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Copanlisib	Aliqopa	J9057	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Crizotinib - oral	Xalkori	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Cyclophosphamide - inj	Cytoxan, Endoxan-Asta	J9070	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Cyclophosphamide - inj (auromedic)	Cyclophosphamide - inj (auromedics) 10 mg	J9071	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Cytarabine	Ara-C	J9100	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Cytarabine-Liposome	DepoCyt	J9098	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Dabrafenib - oral	Tafinlar	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Dacarbazine	DTIC-Dome	J9130	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Dacomitinib - oral	Vizimpro	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Dactinomycin	Cosmegen, Actinomycin	J9120	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Daratumumab	Darzalex	J9145	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Daratumumab and hyaluronidase-fihj	Darzalex Faspro	J9144	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Darbepoetin alfa	Aranesp	J0881	Medical Oncology - SPORT	Supportive	INJECTABLE	◆	Y	
Darolutamide - oral	Nubeqa	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Dasatinib - oral	Sprycel	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	

Effective: 07/01/22

Outpatient Medical Oncology Program

Description	Alt Descriptions	HCPCS Code	Program	Drug Class	Administration Technique	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Daunorubicin	Cerubidine	J9150	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Decitabine	Dacogen	J0894	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Decitabine and cedazuridine - oral	Inqovi	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Degarelix	Firmagon	J9155	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Denosumab	Xgeva, Prolia	J0897	Medical Oncology - SPORT	Supportive	INJECTABLE	◆ Excluding Xgeva	Y	
Dinutuximab	Unituxin	C9399	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Dinutuximab	Unituxin	J9999	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Docetaxel	Taxotere	J9171	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Dostarlimab-gly	Jemperli	J9272	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Doxorubicin HCL	Adriamycin	J9000	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Doxorubicin HCL (liposomal)	Doxil, Doxorubicin HCL (Liposomal) not otherwise specified	Q2050	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Durvalumab	Imfinzi	J9173	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Duvelisib - oral	Copiktra	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Elotuzumab	Empliciti	J9176	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Enasidenib - oral	IDHIFA	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Encorafenib - oral	Braftovi	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Enfortumab vedotin-efv	Padcev	J9177	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Entrectinib - oral	Rozlytrek	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Enzalutamide - oral	Xtandi	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Epirubicin	Ellence	J9178	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Epoetin alfa	Epogen, Procrit	J0885	Medical Oncology - SPORT	Supportive	INJECTABLE	◆	Y	
Epoetin alfa-epbx	Retacrit	Q5106	Medical Oncology - SPORT	Supportive	INJECTABLE	◆	Y	
Erdafitinib-oral	Balversa	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Eribulin mesylate	Halaven	J9179	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Erlotinib - oral	Tarceva	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Estramustine - oral	Emcyt	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Etoposide - inj	Toposar, VePesid, Etopophos	J9181	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Etoposide - oral	Toposar	J8560	Medical Oncology - CHEMO	Primary	ORAL		Y	Medicare Part B
Everolimus - oral	Afinitor	J8999	Medical Oncology - CHEMO	Primary	ORAL	◆	Y	
Fam-trastuzumab deruxtecan-nxki	Enhertu	J9358	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Fedratinib - oral	Inrebic	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Filgrastim	Neupogen	J1442	Medical Oncology - SPORT	Supportive	INJECTABLE	◆	Y	
Filgrastim-aafi	Nivestym	Q5110	Medical Oncology - SPORT	Supportive	INJECTABLE	◆	Y	

Effective: 07/01/22

Outpatient Medical Oncology Program

Description	Alt Descriptions	HCPCS Code	Program	Drug Class	Administration Technique	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Filgrastim-ayow	Releuko	C9096	Medical Oncology - SPORT	Supportive	INJECTABLE	◆	Y	NOC Code: C9096 replacing NOC Code: C9399 effective: 07/01/22
Filgrastim-ayow	Releuko	J9999	Medical Oncology - SPORT	Supportive	INJECTABLE	◆	Y	
Filgrastim-sndz	Zarxio	Q5101	Medical Oncology - SPORT	Supportive	INJECTABLE	◆	Y	
Floxuridine	FUDR	J9200	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Fludarabine Phosphate	Fludara, Oforta	J9185	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Fluoxymesterone - oral	Androxy	J8499	Medical Oncology - CHEMO	Primary	ORAL		Y	
Fosaprepitant	Emend	J1453	Medical Oncology - SPORT	Supportive - Antiemetic	INJECTABLE		Y	
Fosnetupitant/Palonosetron	Akynzeo	J1454	Medical Oncology - SPORT	Supportive - Antiemetic	INJECTABLE		Y	
Fulvestrant	Faslodex	J9395	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Gefitinib - oral	Iressa	J8565	Medical Oncology - CHEMO	Primary	ORAL		Y	
Gemcitabine	Gemzar	J9201	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Gemcitabine HCL in NaCL	Infugem	J9198	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Gemcitabine Hydrochloride (accord)		J9196	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Gemtuzumab Ozogamicin	Mylotarg	J9203	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Gilteritinib - oral	Xospata	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Glasdegib - oral	Daurismo	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Goserelin acetate implant	Zoladex	J9202	Medical Oncology - CHEMO	Primary	INJECTABLE	◆	Y	
Granisetron - subcutaneous	Sustol	J1627	Medical Oncology - SPORT	Supportive - Antiemetic	INJECTABLE		Y	
Histrelin Implant	Vantas	J9225	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Ibrutinib - oral	Imbruvica	J8999	Medical Oncology - CHEMO	Primary	ORAL	◆	Y	
Idarubicin HCL - inj	Idamycin	J9211	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Idelalisib - oral	Zydelig	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Ifosfamide	Ifex, Mitoxana	J9208	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Imatinib - oral	Gleevec	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Imatinib - oral	Gleevec	S0088	Medical Oncology - CHEMO	Primary	ORAL		Y	
Infigratinib - oral	Truseltiq	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Inotuzumab Ozogamicin	Besponsa	J9229	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Interferon, alfa-2b, recombinant	Intron A	J9214	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Interferon, gamma-1b	Actimmune	J9216	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Ipilimumab	Yervoy	J9228	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Irinotecan	Camptosar	J9206	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Irinotecan Liposome	Onivyde	J9205	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	

Effective: 07/01/22

Outpatient Medical Oncology Program

Description	Alt Descriptions	HCPCS Code	Program	Drug Class	Administration Technique	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Isatuximab-irfc	Sarcisa	J9227	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Ivosidenib - oral	Tibsovo	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Ixabepilone	Ixempra	J9207	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Ixazomib - oral	Ninlaro	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Lanreotide	Somatuline Depot	J1930	Medical Oncology - CHEMO	Primary	INJECTABLE	◆	Y	
Lanreotide (Cipla)		J1930	Medical Oncology - CHEMO	Primary	INJECTABLE	◆	Y	
Lapatinib - oral	Tykerb	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Larotrectinib - oral	Vitrakvi	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Lenalidomide - oral	Revlimid	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Lenvatinib - oral	Lenvima	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Leucovorin - inj		J0640	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Leucovorin - oral	Leucovorin	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Leuprolide Acetate (J1950: 3.75mg)	Eligard, Lupron Depot, Lupron, Leuprolide Acetate	J1950	Medical Oncology - CHEMO	Primary	INJECTABLE	◆ Excluding Eligard	Y	
Leuprolide Acetate (J9217: 7.5mg)	Eligard, Lupron Depot, Lupron, Leuprolide Acetate	J9217	Medical Oncology - CHEMO	Primary	INJECTABLE	◆ Excluding Eligard	Y	
Leuprolide Acetate (J9218: 1mg)	Lupron	J9218	Medical Oncology - CHEMO	Primary	INJECTABLE	◆ Excluding Eligard	Y	
Leuprolide Mesylate	Camcevi	J1952	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Levoleucovorin	Fusilev	J0641	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Levoleucovorin	Khapzory	J0642	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Liposome-encapsulated combination of Daunorubicin and Cytarabine	Vyxeos	J9153	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Lomustine - oral	Gleostine, CCNU	S0178	Medical Oncology - CHEMO	Primary	ORAL		Y	
Loncastuximab tesirine-lpyl	Zynlonta	J9359	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Lorlatinib - oral	Lorbrena	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Lurbinectedin	Zepzelca	J9223	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Luspatercept-aamt	Reblozyl	J0896	Medical Oncology - SPORT	Supportive	INJECTABLE	◆	Y	
Margetuximab-cmkb	Margenza	J9353	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Mechlorethamine - topical	Valchlor	J9999	Medical Oncology - CHEMO	Primary	TOPICAL		Y	
Melphalan HCL - inj	Evomela	J9246	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Melphalan HCL - NOS inj	Alkeran	J9245	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Mesna	Mesnex	J9209	Medical Oncology - SPORT	Supportive	INJECTABLE		Y	
Methotrexate Sodium (J9250: 5mg)	Folex, Methotrexate	J9250	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Methotrexate Sodium (J9260: 50mg)	Folex, Methotrexate	J9260	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Midostaurin - oral	Rydapt	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Mitomycin	Jelmyto	J9281	Medical Oncology - CHEMO	Primary	PYELOCALYCEAL		Y	Medicare Part B

Effective: 07/01/22

Outpatient Medical Oncology Program

Description	Alt Descriptions	HCPCS Code	Program	Drug Class	Administration Technique	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Mitomycin	Mutamycin	J9280	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Mitotane - oral	Lysodren	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Mitoxantrone HCL	Novantrone	J9293	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Mobocertinib - oral	Exkivity	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Mogamulizumab-kpkc	Poteligeo	J9204	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Moxetumomab pasudotox-tdfk	Lumoxiti	J9313	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Naxitamab-ggqk	Danyelza	J9348	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Necitumumab	Portrazza	J9295	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Nelarabine	Arranon	J9261	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Neratinib - oral	Nerlynx	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Netupitant/Palonosetron - oral	Akynzeo	J8655	Medical Oncology - SPORT	Supportive - Antiemetic	ORAL		Y	
Nilotinib - oral	Tasigna	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Niraparib - oral	Zejula	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Nivolumab	Opdivo	J9299	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Nivolumab and Relatlimab-rmbw	Opdualag	C9399	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Nivolumab and Relatlimab-rmbw	Opdualag	J9999	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Obinutuzumab	Gazyva	J9301	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Octreotide depot	Sandostatin	J2353	Medical Oncology - SPORT	Supportive	INJECTABLE	◆	Y	
Octreotide depot	Sandostatin	J2353	Medical Oncology - CHEMO	Primary	INJECTABLE	◆	Y	
Octreotide non-depot	Sandostatin	J2354	Medical Oncology - SPORT	Supportive	INJECTABLE	◆	Y	
Octreotide non-depot	Sandostatin	J2354	Medical Oncology - CHEMO	Primary	INJECTABLE	◆	Y	
Ofatumumab	Arzerra	J9302	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Olaparib - oral	Lynparza	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Omacetaxine	Synribo	J9262	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Osimertinib - oral	Tagrisso	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Oxaliplatin	Eloxatin	J9263	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Paclitaxel	Nov-Onxol, Taxol	J9267	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Paclitaxel (albumin-bound)	Abraxane	J9264	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Pacritinib - oral	Vonjo	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Palbociclib - oral	Ibrance	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Palonosetron	Aloxi	J2469	Medical Oncology - SPORT	Supportive - Antiemetic	INJECTABLE		Y	
Pamidronate Disodium	Aredia	J2430	Medical Oncology - SPORT	Supportive	INJECTABLE		Y	
Panitumumab	Vectibix	J9303	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	

Effective: 07/01/22

Outpatient Medical Oncology Program

Description	Alt Descriptions	HCPCS Code	Program	Drug Class	Administration Technique	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Pazopanib - oral	Votrient	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Pegaspargase	Oncaspar	J9266	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Pegfilgrastim, excludes biosimilar, 0.5 mg	Neulasta	J2506	Medical Oncology - SPORT	Supportive	INJECTABLE		Y	
Pegfilgrastim-apgf	Nyvepria	Q5122	Medical Oncology - SPORT	Supportive	INJECTABLE		Y	
Pegfilgrastim-bmez	Ziextenzo	Q5120	Medical Oncology - SPORT	Supportive	INJECTABLE		Y	
Pegfilgrastim-cbqv	Udenyca	Q5111	Medical Oncology - SPORT	Supportive	INJECTABLE		Y	
Pegfilgrastim-jmdb	Fulphila	Q5108	Medical Oncology - SPORT	Supportive	INJECTABLE		Y	
Peginterferon, alfa-2a	Pegasys	J3590	Medical Oncology - CHEMO	Primary	INJECTABLE	◆	Y	
Peginterferon, alfa-2a	Pegasys	S0145	Medical Oncology - CHEMO	Primary	INJECTABLE	◆	Y	
Peginterferon, alfa-2b	PegIntron	J3590	Medical Oncology - CHEMO	Primary	INJECTABLE	◆	Y	
Peginterferon, alfa-2b	PegIntron	S0148	Medical Oncology - CHEMO	Primary	INJECTABLE	◆	Y	
Pembrolizumab	Keytruda	J9271	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Pemetrexed	Alimta, Pemetrexed not otherwise specified	J9305	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Pemetrexed	Pemfexy	J9304	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Pemigatinib - oral	Pemazyre	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Pentostatin	Nipent	J9268	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Pertuzumab	Perjeta	J9306	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Pertuzumab / trastuzumab / hyaluronidase-zzxf	Phesgo	J9316	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Pexidartinib - oral	Turalio	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Polatuzumab vedotin-piiq	Polivy	J9309	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Pomalidomide - oral	Pomalyst	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Ponatinib - oral	Iclusig	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Porfimer Sodium	Photofrin	J9600	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Pralatrexate	Folotyn	J9307	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Pralsetinib - oral	Gavreto	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Procarbazine - oral	Matulane	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Procarbazine - oral	Matulane	S0182	Medical Oncology - CHEMO	Primary	ORAL		Y	
Ramucirumab	Cyramza	J9308	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Regorafenib - oral	Stivarga	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Relugolix - oral	Orgovyx	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Ribociclib - oral	Kisqali	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Ripretinib - oral	Qinlock	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Rituximab	Rituxan	J9312	Medical Oncology - CHEMO	Primary	INJECTABLE	◆	Y	

Effective: 07/01/22

Outpatient Medical Oncology Program

Description	Alt Descriptions	HCPCS Code	Program	Drug Class	Administration Technique	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Rituximab and Hyaluronidase Human	Rituxan Hycela	J9311	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Rituximab-abbs	Truxima	Q5115	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	◆	Y	
Rituximab-arxx	Riabni	Q5123	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	◆	Y	
Rituximab-pvvr	Ruxience	Q5119	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	◆	Y	
Rolapitant - oral	Varubi	J8670	Medical Oncology - SPORT	Supportive - Antiemetic	ORAL		Y	
Romidepsin (lyophilized)	Istodax	J9319	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Romidepsin (non-lyophilized)		J9318	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Ropeginterferon alfa-2b-njft	Besremi	C9399	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Ropeginterferon alfa-2b-njft	Besremi	J9999	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Rucaparib - oral	Rubraca	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Ruxolitinib - oral	Jakafi	J8999	Medical Oncology - CHEMO	Primary	ORAL	◆	Y	
Sacituzumab govitecan-hziy	Trodelyv	J9317	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Sargramostim	Leukine	J2820	Medical Oncology - SPORT	Supportive	INJECTABLE		Y	
Selinexor - oral	Xpovio	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Selpercatinib - oral	Retevmo	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Selumetinib - oral	Koselugo	J8999	Medical Oncology - CHEMO	Primary	ORAL	◆	Y	
Siltuximab	Sylvant	J2860	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Sipuleucel-T	Provenge	Q2043	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Sirolimus protein-bound particles for injectable suspension (albumin bound)	Fyarro	J9331	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	Permanent CPT Code: J9331 effective: 07/01/22
Sonidegib - oral	Odomzo	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Sorafenib Tosylate - oral	Nexavar	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Sotorasib - oral	Lumakras	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Streptozocin	Zanosar	J9320	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Sunitinib - oral	Sutent	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Tafasitamab-cxh	Monjuvi	J9349	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Tagraxofusp-erzs	Elzonris	J9269	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Talazoparib - oral	Talzenna	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Talimogene Laherparepvec	Imlygic	J9325	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Tazemetostat - oral	Tazverik	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Tbo-filgrastim	Granix	J1447	Medical Oncology - SPORT	Supportive	INJECTABLE		Y	
Tebentafusp-tebn	Kimtrak	C9095	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	NOC Code: C9095 replacing NOC Code: C9399 effective: 07/01/22
Tebentafusp-tebn	Kimtrak	J9999	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	

Effective: 07/01/22

Outpatient Medical Oncology Program

Description	Alt Descriptions	HCPCS Code	Program	Drug Class	Administration Technique	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Telotristat ethyl - oral	Xermelo	J8499	Medical Oncology - SPORT	Supportive	ORAL		Y	
Telotristat ethyl - oral	Xermelo	J8999	Medical Oncology - SPORT	Supportive	ORAL		Y	
Temozolomide - inj	Temodar	J9328	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Temozolomide - oral	Temodar	J8700	Medical Oncology - CHEMO	Primary	ORAL		Y	Medicare Part B
Temsirolimus	Torisel	J9330	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Teniposide	Vumon	Q2017	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Tepotinib - oral	Tepmetko	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Thalidomide - oral	Thalomid	J8999	Medical Oncology - CHEMO	Primary	ORAL	◆	Y	
Thiotepa	Thioplex	J9340	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Tisotumab vedotin-tftv	Tivdak	J9273	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Tivozanib - oral	Fotivda	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Tocilizumab	Actemra	J3262	Medical Oncology - CHEMO	Primary	INJECTABLE	◆	Y	
Topotecan - inj	Hycamtin	J9351	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Topotecan - oral	Hycamtin	J8705	Medical Oncology - CHEMO	Primary	ORAL		Y	Medicare Part B
Trabectedin	Yondelis	J9352	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Trametinib - oral	Mekinist	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Trastuzumab	Herceptin	J9355	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Trastuzumab and hyaluronidase-oysk	Herceptin Hylecta	J9356	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Trastuzumab-anns	Kanjinti	Q5117	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE		Y	
Trastuzumab-dkst	Ogivri	Q5114	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE		Y	
Trastuzumab-dttb	Ontruzant	Q5112	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE		Y	
Trastuzumab-pkrb	Herzuma	Q5113	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE		Y	
Trastuzumab-qyyp	Trazimera	Q5116	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE		Y	
Trifluridine/Tipiracil - oral	Lonsurf	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Trilaciclib	Cosela	J1448	Medical Oncology - SPORT	Supportive	INJECTABLE		Y	
Triptorelin Pamoate	Trelstar	J3315	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Tucatinib - oral	Tukysa	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Umbralisib - oral	Ukoniq	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Valrubicin	Valstar	J9357	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Vandetanib - oral	Caprelsa	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Vemurafenib - oral	Zelboraf	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Venetoclax - oral	Venclexta	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Vinblastine Sulfate	Velban	J9360	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	

Effective: 07/01/22

Outpatient Medical Oncology Program

Description	Alt Descriptions	HCPCS Code	Program	Drug Class	Administration Technique	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Vincristine Sulfate	Oncovin, Vincasar PFS	J9370	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Vincristine Sulfate Liposome	Marqibo	J9371	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Vinorelbine Tartrate	Navelbine	J9390	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Vismodegib - oral	Erivedge	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Vorinostat - oral	Zolinza	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Zanubrutinib - oral	Brukinsa	J8999	Medical Oncology - CHEMO	Primary	ORAL		Y	
Zivafibercept	Zaltrap	J9400	Medical Oncology - CHEMO	Primary	INJECTABLE		Y	
Zoledronic Acid	Zoledronic Acid	J3489	Medical Oncology - SPORT	Supportive	INJECTABLE	◆	Y	